MetaCap

Dogwood Therapeutics (DWTX) vs OS Therapies (OSTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OS Therapies (OSTX) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 53.0% versus a loss of 83.7%. OS Therapies is the larger company by market cap ($42.0 million vs $39.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DWTX-83.68%OSTX-53.04%
+37%-26%-89%
Nov 21, 20251 yearNov 20, 2026
DWTX-78.10%OSTX-79.92%
+177%+41%-94%
Jul 29, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DWTX versus OSTX key metrics
MetricDWTXOSTX
Share price$1.04$0.803
Market cap$39.57M$42.00M
1-day change-2.36%-2.12%
YTD return-75.12%-42.64%
1-year return-83.68%-53.04%
5-year return-99.16%—
P/E ratio (TTM)0.10—
Forward P/E—2.29
EPS (TTM)$10.26$-1.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-34.26M$-28.75M
52-week high$7.04$2.25
52-week low$0.901$0.58
Distance from 52-week high-85.31%-64.31%
Analyst consensusnonestrong_buy
Avg. price target upside+1252.66%+958.53%
Average volume89.88K722.66K
Shares outstanding38.23M52.30M
Employees84
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OSTX has outperformed DWTX by 30.6 percentage points over the past year.

About Dogwood Therapeutics

DWTX stock →

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About OS Therapies

OSTX stock →

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

DWTX vs OSTX FAQ

Which is bigger, Dogwood Therapeutics or OS Therapies?

OS Therapies (OSTX) is larger, with a market capitalization of $42.00M compared with $39.57M for Dogwood Therapeutics (DWTX).

Which stock has performed better over the past year, DWTX or OSTX?

OSTX returned -53.04% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.

Are Dogwood Therapeutics and OS Therapies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons